This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hims & Hers Redefines Virtual Care With Integrated Tech Platforms
by Debanjana Dey
HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.
Medifast's Q2 Earnings Beat Estimates, Lower Revenues Hurt Margins
by Zacks Equity Research
MED's second-quarter 2025 earnings and sales decline as active earning OPTAVIA coaches dipped, hit by client acquisition.
Kraft Heinz Q2 Earnings Beat Estimates, Organic Sales Down 2% Y/Y
by Zacks Equity Research
KHC tops Q2 estimates despite declines in earnings and organic sales, as pricing gains fail to offset weak volumes.
Health Meets Lifestyle: How Hims & Hers Is Reshaping Everyday Wellness
by Zacks Equity Research
HIMS is transforming digital wellness with personalized care, over 30 million telehealth consultations, and a Gen Z-aligned platform.
Mondelez (MDLZ) Down 2.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Mondelez (MDLZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast (MED) Up 10.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mondelez's Innovation & Brand Strength Fueling Long-Term Growth
by Zacks Equity Research
MDLZ's innovation, strong brand portfolio and global expansion position it for sustained growth, making the stock an appealing choice for long-term investors.
Medifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/Y
by Zacks Equity Research
MED's first-quarter results show challenges from fewer active OPTAVIA Coaches. Nonetheless, the company is focusing on revitalizing its coach base for growth.
Medifast to Report Q1 Earnings: What Investors Should Expect
by Zacks Equity Research
MED's first-quarter results may show challenges in customer acquisition amid market headwinds and shifting consumer trends.
Medifast Trades Near 52-Week Low: What's the Best Move Now?
by Zacks Equity Research
MED faces steep revenue declines and coach losses but aims to rebound through innovation, marketing and new GLP-1-focused initiatives.
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
by Zacks Equity Research
Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.
Medifast (MED) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 137.04% and 7.70%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
by Zacks Equity Research
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space.
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
by Zacks Equity Research
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.
Medifast (MED) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Medifast (MED) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Medifast (MED) stock based on the movements in the options market lately.
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
by Zacks Equity Research
MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success.
Are Investors Undervaluing MEDIFAST (MED) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
by Zacks Equity Research
Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter.
Medifast (MED) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 333.33% and 3.48%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Medifast Gears Up for Q3 Earnings: Here's What You Should Know
by Zacks Equity Research
MED's Q3 results may reflect customer acquisition challenges and a decline in active earning OPTAVIA Coaches due to the increasing adoption of GLP-1 medications.
Medifast Drives Growth With Weight Loss Transformation Strategies
by Zacks Equity Research
MED is striving to excel in the evolving weight loss market where GLP-1 medication adoption is reshaping the industry dynamics amid macroeconomic challenges.
Medifast Trades Near 52-Week Low: Buy, Hold or Sell MED Stock?
by Zacks Equity Research
Amid hurdles like competition and a dynamic consumer landscape, Medifast is taking steps to realign its strategy and capitalize on emerging opportunities.
Medifast (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast's (MED) Strategies Aid Amid Evolving Market Demands
by Zacks Equity Research
Medifast (MED) is making efforts to thrive in the rapidly evolving weight loss market, as the adoption of GLP-1 medications reshapes industry dynamics.